Active — Not RecruitingNot Applicable

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

United States12,500 participantsStarted 2022-11-01

Plain-language summary

The purpose of this study is to reduce the exposure of broad-spectrum antimicrobials by optimizing the rapid detection of CAP pathogens and improving rates of de-escalation following negative cultures. To accomplish this, we will perform a 3-year, pragmatic, multicenter 2 X 2 factorial cluster randomized controlled trial with four arms: a) rapid diagnostic testing b) pharmacist-led de-escalation c) rapid diagnostic testing + pharmacist-led de-escalation and d) usual care

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Men or women greater than or equal to 18 years of age
✓. Admitted to a participating (i.e. enrolled and randomized) hospital
✓. Admitting diagnosis of pneumonia

Exclusion criteria

✕. Admission to intensive care unit within 24 hours of hospital admission
✕. Comfort care measures only
✕. Cystic fibrosis
✕. Discharged from an acute care hospital in the past week
✕. Patients not eligible for empiric therapy due to a known pathogen (any positive blood or respiratory cultures in the 72 hours prior to admission)

What they're measuring

Number of days of broad-spectrum antibiotic therapy

Timeframe: first 21 days of admission

Trial details

NCT IDNCT05568654

SponsorThe Cleveland Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-31

View on ClinicalTrials.gov More Community-Acquired Pneumonia trials